At Texas A&M University in College Station, Dr. Ashok Shetty and his team have demonstrated something that neuroscience long considered impossible: brain aging can be reversed. In a landmark study published in the Journal of Extracellular Vesicles, researchers showed that a simple nasal spray restored memory, reduced chronic inflammation, and improved brain cell function after just two doses.
The discovery addresses one of aging's most stubborn biological problems. For years, scientists have understood that aging brains experience persistent low-level inflammation—a process known as "neuroinflammaging"—that interferes with memory, thinking, and the brain's capacity to adapt. This chronic inflammation is a major contributor to neurodegenerative diseases like dementia and Alzheimer's, conditions that have become increasingly urgent public health concerns. In the United States alone, annual dementia cases are expected to surge from roughly 514,000 in 2020 to around 1 million by 2060.
The experimental treatment works through microscopic biological particles called extracellular vesicles, which naturally transport genetic material between cells. The team, led by Dr. Shetty alongside senior research scientists Dr. Madhu Leelavathi Narayana and Dr. Maheedhar Kodali, loaded these particles with microRNAs—molecules that regulate important biological processes in the brain. By delivering the therapy through nasal spray, researchers bypassed the brain's protective barrier and allowed the treatment to reach brain tissue directly, avoiding invasive procedures.
Once inside the brain, the spray targeted the root causes of age-related decline. It suppressed inflammatory systems such as the NLRP3 inflammasome and the cGAS-STING signaling pathways, both strongly linked to aging-related brain inflammation. But the treatment did something equally important: it restored mitochondrial function. Mitochondria are the tiny structures inside cells that produce energy; when aging and inflammation damage them, brain cells become less efficient and more vulnerable to decline. By reactivating the brain's mitochondria and reducing oxidative stress, the therapy gave what Dr. Narayana called the brain's "spark back."
The results extended far beyond laboratory measurements. Behavioral testing showed that treated subjects performed significantly better on memory and recognition tasks. They were more successful at identifying familiar objects, recognizing new ones, and detecting changes in their surroundings compared to untreated controls. Most strikingly, these improvements appeared quickly and lasted for months after only two doses—a dramatic departure from the typical months of medication or invasive procedures currently used to manage cognitive decline.
What makes the findings particularly remarkable is their consistency. The study found similar treatment responses across both sexes, something Dr. Shetty emphasized as "universal" and relatively uncommon in biomedical research. This universality suggests the approach could eventually benefit a broad population.
Looking ahead, the implications extend beyond aging alone. The therapy could potentially help stroke patients recover brain function or slow cognitive decline linked to aging in general. Dr. Shetty frames the work as fundamentally redefining what aging means. "Our approach redefines what it means to grow old," he said. "We're aiming for successful brain aging: keeping people engaged, alert and connected. Not just living longer, but living smarter and healthier."
As the team continues to develop and scale the therapy, a simple nasal spray could one day replace the invasive, risky procedures and extended medication regimens that currently dominate dementia treatment. For millions facing cognitive decline, this research offers something rare: genuine hope grounded in measurable results.